CDK12 and triple-negative breast carcinoma: For this, we performed RNA sequencing (RNA-seq) in MDA-MB-231 cells, choosing triple-negative breast cancer cells as the relevant therapeutic context for CDK12/13–cyclin K inactivation16,18.